Notable from the relatively high percentage of PTEN loss in prostate cancer, several groups have investigated its potential role in the response to radiotherapy, targeted therapies and conventional chemotherapy, trying to overcome the absence of a uniformly accepted assay to measure PTEN levels [73]. Here, PTEN is linked to Familial prostate cancer.